A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the safety and tolerance of low-dose versus high-dose cysteamine administered concurrently with zidovudine (AZT). To determine the pharmacokinetics and effects on immune function and viral load in patients receiving these drug regimens.
Condition or disease
Drug: CysteamineDrug: Zidovudine
Patients receive high or low doses of cysteamine plus AZT or placebo plus AZT. The target dose of cysteamine is determined by titration of the dose over a 6-week period, after which the patient receives 24 additional weeks of treatment. An initial cohort of 36 patients will be enrolled in a 10-week pilot phase. Accrual will be temporarily suspended while data from the pilot phase is assessed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
13 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chemoprophylaxis for Pneumocystis carinii pneumonia, candidiasis, Mycobacterium tuberculosis, and herpes as prescribed by the investigator.
Recombinant erythropoietin and G-CSF if clinically indicated.
Patients must have:
Documented HIV infection.
CD4 count 300 - 500 cells/mm3.
Prior AZT therapy for at least 3 months but less than 12 months prior to study entry.
No past or current AIDS-defining opportunistic infection.
Patients with the following symptoms or conditions are excluded:
Kaposi's sarcoma requiring systemic therapy.
Active malignancy other than basal cell carcinoma or in situ cervical carcinoma.
Antiretroviral therapy other than AZT.
Investigational HIV drugs/therapies other than study drug.
Cytotoxic chemotherapy including Adriamycin, bleomycin, and vincristine.
Patients with the following prior condition are excluded:
History of treatment-limiting intolerance to 500-600 mg AZT daily as manifested by the same recurrent grade 3 toxicity or any prior grade 4 toxicity.
Prior antiretroviral therapy other than AZT.
AZT for at least 3 months but no more than 12 months prior to study entry.